In newly diagnosed metastatic non-squamous NSCLC patients, which (if any) genomic targets are you routinely testing for besides EGFR and ALK?   

If KRAS, EGFR, and ALK are negative, I also evaluate tumors for ROS1 (with crizotinib now approved for this indication), MET (exon 14 skipping or amplification), HER2, BRAF V600E, RET and NTRK (mainly for clinical trial options). This is usually part of a panel of 200 or so genes. While I ...